Neurofibromatosis 2011: a report of the Children’s Tumor Foundation Annual Meeting
Date
2012-03Author
Subject
Metadata
Show full item recordAbstract
The 2011 annual meeting of the Children's Tumor Foundation, the annual gathering of the neurofibromatosis (NF) research and clinical communities, was attended by 330 participants who discussed integration of new signaling pathways into NF research, the appreciation for NF mutations in sporadic cancers, and an expanding pre-clinical and clinical agenda. NF1, NF2, and schwannomatosis collectively affect approximately 100,000 persons in US, and result from mutations in different genes. Benign tumors of NF1 (neurofibroma and optic pathway glioma) and NF2 (schwannoma, ependymoma, and meningioma) and schwannomatosis (schwannoma) can cause significant morbidity, and there are no proven drug treatments for any form of NF. Each disorder is associated with additional manifestations causing morbidity. The research presentations described in this review covered basic science, preclinical testing, and results from clinical trials, and demonstrate the remarkable strides being taken toward understanding of and progress toward treatments for these disorders based on the close interaction among scientists and clinicians.
Collections
Publisher
Place of Publication
Journal
Volume
Issue
Pagination
Author URL
Recommended, similar items
The following license files are associated with this item:
Related items
Showing items related by title, author, creator and subject.
-
Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical use
Bettegowda, C; Upadhayaya, M; Evans, DG; Kim, A; Mathios, D; Hanemann, CO (American Academy of NeurologyUnited States, 2021-07-06)<jats:sec><jats:title>Objective:</jats:title><jats:p>As clinically validated biomarkers for neurofibromatosis 1 (NF1) and neurofibromatosis 2 (NF2), have not been identified to date, we wanted to determine whether ... -
Current whole-body MRI applications in the neurofibromatoses
Ahlawat, S; Fayad, LM; Khan, MS; Bredella, MA; Harris, GJ; Evans, DG; Farschtschi, S; Jacobs, MA; Chhabra, A; Salamon, JM; Wenzel, R; Mautner, VF; Dombi, E; Cai, W; Plotkin, SR; Blakeley, JO; Hanemann, Clemens Oliver (Ovid Technologies (Wolters Kluwer Health)United States, 2016-08-16)OBJECTIVES: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for ... -
Phase 0 trial investigating the intra-tumoural concentration and activity of Sorafenib in Neurofibromatosis type 2
Hanemann, Clemens Oliver; Ammoun, Sylwia; Evans, G; Hilton, DA; Streeter, Adam; Hayward, C (BMJ Publishing GroupEngland, 2019-02-04)